Patrick G Kehoe

List of Publications by Year in Descending Order

192 papers	12,398 citations	50 h-index	107 g-index
214 ext. papers	14,851 ext. citations	7 avg, IF	5.96 L-index

#	Paper	IF	Citations
192	Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping.. *Alzheimer's Research and Therapy*, **2022**, 14, 22	9	
191	New insights into the genetic etiology of Alzheimer's disease and related dementias.. *Nature Genetics*, **2022**,	36.3	27
190	Losartan to slow the progression of mild-to-moderate Alzheimer's disease through angiotensin targeting: the RADAR RCT. *Efficacy and Mechanism Evaluation*, **2021**, 8, 1-72	1.7	0
189	Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet Neurology, The*, **2021**, 20, 895-906	24.1	4
188	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. *Nature Communications*, **2021**, 12, 3417	17.4	23
187	Lipid Profiling of Alzheimer's Disease Brain Highlights Enrichment in Glycerol(phospho)lipid, and Sphingolipid Metabolism. *Cells*, **2021**, 10,	7.9	2
186	Zibotentan, an Endothelin A Receptor Antagonist, Prevents Amyloid-β-Induced Hypertension and Maintains Cerebral Perfusion. *Journal of Alzheimer's Disease*, **2020**, 73, 1185-1199	4.3	6
185	UK consensus on pre-clinical vascular cognitive impairment functional outcomes assessment: Questionnaire and workshop proceedings. *Journal of Cerebral Blood Flow and Metabolism*, **2020**, 40, 1402-1414	7.3	0
184	Association of combination statin and antihypertensive therapy with reduced Alzheimer's disease and related dementia risk. *PLoS ONE*, **2020**, 15, e0229541	3.7	19
183	Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis. *Neurology* , **2020**, 94, e267-e281	6.5	38
182	ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer's disease. *Acta Neuropathologica*, **2020**, 139, 485-502	14.3	56
181	BCAT-induced autophagy regulates Aβ load through an interdependence of redox state and PKC phosphorylation-implications in Alzheimer's disease. *Free Radical Biology and Medicine*, **2020**, 152, 755-766	7.8	7
180	Baseline Results: The Association Between Cardiovascular Risk and Preclinical Alzheimer's Disease Pathology (ASCEND) Study. *Journal of Alzheimer's Disease*, **2020**, 75, 109-117	4.3	10
179	Elevated cerebrospinal fluid sodium in hypertensive human subjects with a family history of Alzheimer's disease. *Physiological Genomics*, **2020**, 52, 133-142	3.6	3
178	Cognitive impact of COVID-19: looking beyond the short term. *Alzheimer's Research and Therapy*, **2020**, 12, 170	9	76
177	Evidence that the Kennedy and polyamine pathways are dysregulated in human brain in cases of dementia with Lewy bodies. *Brain Research*, **2020**, 1743, 146897	3.7	0
176	Comparison of Antihypertensive Drug Classes for Dementia Prevention. *Epidemiology*, **2020**, 31, 852-859	3.1	2

175	Small RNA modifications in Alzheimer's disease. *Neurobiology of Disease*, **2020**, 145, 105058	7.5	16
174	Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study. *International Journal of Epidemiology*, **2020**, 49, 1132-1140	7.8	27
173	Association of combination statin and antihypertensive therapy with reduced Alzheimer disease and related dementia risk **2020**, 15, e0229541		
172	Association of combination statin and antihypertensive therapy with reduced Alzheimer disease and related dementia risk **2020**, 15, e0229541		
171	Association of combination statin and antihypertensive therapy with reduced Alzheimer disease and related dementia risk **2020**, 15, e0229541		
170	Association of combination statin and antihypertensive therapy with reduced Alzheimer disease and related dementia risk **2020**, 15, e0229541		
169	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. *Alzheimer Research and Therapy*, **2019**, 11, 74	9	16
168	Challenges to and Facilitators of Recruitment to an Alzheimer's Disease Clinical Trial: A Qualitative Interview Study. *Journal of Alzheimer Disease*, **2019**, 69, 1067-1075	4.3	9
167	Divergence in the activity of the N- and C- catalytic domains of ACE1 - implications for the role of the renin-angiotensin system in Alzheimer's disease. *Acta Neuropathologica Communications*, **2019**, 7, 57	7.3	3
166	The Epistasis Project: A Multi-Cohort Study of the Effects of BDNF, DBH, and SORT1 Epistasis on Alzheimer's Disease Risk. *Journal of Alzheimer Disease*, **2019**, 68, 1535-1547	4.3	5
165	Effect of Visit-to-Visit Blood Pressure Variability on Cognitive and Functional Decline in Mild to Moderate Alzheimer's Disease. *Journal of Alzheimer Disease*, **2019**, 68, 1499-1510	4.3	4
164	Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease. *Journal of Alzheimer Disease*, **2019**, 72, 525-535	4.3	9
163	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A tau, immunity and lipid processing. *Nature Genetics*, **2019**, 51, 414-430	36.3	917
162	The Coming of Age of the Angiotensin Hypothesis in Alzheimer's Disease: Progress Toward Disease Prevention and Treatment?. *Journal of Alzheimer Disease*, **2018**, 62, 1443-1466	4.3	73
161	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. *Alzheimer and Dementia*, **2018**, 14, 280-292	1.2	136
160	Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease. *Neurobiology of Aging*, **2018**, 62, 244.e1-244.e8	5.6	25
159	What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink. *Alzheimer Research and Therapy*, **2018**, 10, 51	9	6
158	Tools for testing decision-making capacity in dementia. *Age and Ageing*, **2018**, 47, 778-784	3	18

157	The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial. *Journal of Alzheimer's Disease*, **2018**, 61, 803-814	4.3	27
156	Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial. *Journal of Alzheimer's Disease*, **2018**, 61, 815-824	4.3	14
155	Cerebral A□and systemic hypertension. *Journal of Cerebral Blood Flow and Metabolism*, **2018**, 38, 1993-2005	7.3	5
154	O5-06-05: EXPLORING ACE-2 AS A NOVEL THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE **2018**, 14, P1659-P1659		1
153	Evidence That Parietal Lobe Fatty Acids May Be More Profoundly Affected in Moderate Alzheimer's Disease (AD) Pathology Than in Severe AD Pathology. *Metabolites*, **2018**, 8,	5.6	10
152	The association of multiple anti-hypertensive medication classes with Alzheimer's disease incidence across sex, race, and ethnicity. *PLoS ONE*, **2018**, 13, e0206705	3.7	33
151	Altered Expression of Human Mitochondrial Branched Chain Aminotransferase in Dementia with Lewy Bodies and Vascular Dementia. *Neurochemical Research*, **2017**, 42, 306-319	4.6	12
150	Angiotensin-III is Increased in Alzheimer's Disease in Association with Amyloid-□and Tau Pathology. *Journal of Alzheimer's Disease*, **2017**, 58, 203-214	4.3	26
149	Reply: Atherosclerosis and vascular cognitive impairment neuropathological guideline. *Brain*, **2017**, 140, e13	11.2	1
148	The Vascular Impairment of Cognition Classification Consensus Study. *Alzheimer's and Dementia*, **2017**, 13, 624-633	1.2	106
147	Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. *PLoS ONE*, **2017**, 12, e0179521	3.7	36
146	Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies. *European Journal of Epidemiology*, **2017**, 32, 947-959	12.1	23
145	Mutation analysis of sporadic early-onset Alzheimer's disease using the NeuroX array. *Neurobiology of Aging*, **2017**, 49, 215.e1-215.e8	5.6	15
144	Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's Disease. *Metabolites*, **2017**, 7,	5.6	67
143	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. *Health Technology Assessment*, **2017**, 21, 1-192	4.4	19
142	Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-□and tau pathology. *Alzheimer's Research and Therapy*, **2016**, 8, 50	9	107
141	A Validation Study of Vascular Cognitive Impairment Genetics Meta-Analysis Findings in an Independent Collaborative Cohort. *Journal of Alzheimer's Disease*, **2016**, 53, 981-9	4.3	18
140	A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol. *Trials*, **2016**, 17, 324	2.8	5

139	Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome. *Neurobiology of Aging*, **2016**, 38, 151-163	5.6	70
138	Wide-ranging alterations in the brain fatty acid complement of subjects with late Alzheimer's disease as detected by GC-MS. *American Journal of Translational Research (discontinued)*, **2016**, 8, 154-65	3	22
137	Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer's and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink. *BMJ Open*, **2016**, 6, e012044	3	8
136	Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-□(A)□Plaque Load and A□Synthesizing and A□Degrading Enzymes in Frontal Cortex. *Journal of Alzheimer's Disease*, **2016**, 50, 1191-203	4.3	33
135	Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. *Brain*, **2016**, 139, 2957-2969	11.2	141
134	Is Extracorporeal Shockwave Therapy Combined With Isokinetic Exercise More Effective Than Extracorporeal Shockwave Therapy Alone for Subacromial Impingement Syndrome? A Randomized Clinical Trial. *Journal of Orthopaedic and Sports Physical Therapy*, **2016**, 46, 714-25	4.2	11
133	Regional Increase in the Expression of the BCAT Proteins in Alzheimer's Disease Brain: Implications in Glutamate Toxicity. *Journal of Alzheimer's Disease*, **2015**, 45, 891-905	4.3	24
132	DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. *Epigenomics*, **2015**, 7, 533-7	4.4	19
131	Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy. *Journal of Alzheimer's Disease*, **2015**, 44, 153-62	4.3	15
130	The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. *Alzheimer's and Dementia*, **2015**, 11, 195-206.e1	1.2	45
129	Quantitative measurement of [Na+] and [K+] in postmortem human brain tissue indicates disturbances in subjects with Alzheimer's disease and dementia with Lewy bodies. *Journal of Alzheimer's Disease*, **2015**, 44, 851-7	4.3	11
128	Blood type gene locus has no influence on ACE association with Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 1767.e1-1767.e2	5.6	2
127	Investigation of A□phosphorylated at serine 8 (pA)□in Alzheimer's disease, dementia with Lewy bodies and vascular dementia. *Neuropathology and Applied Neurobiology*, **2015**, 41, 428-44	5.2	14
126	Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease. *PLoS ONE*, **2015**, 10, e0119452	3.7	105
125	Age-associated changes of brain copper, iron, and zinc in Alzheimer's disease and dementia with Lewy bodies. *Journal of Alzheimer's Disease*, **2014**, 42, 1407-13	4.3	44
124	The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. *Alzheimer's Research and Therapy*, **2014**, 6, 27	9	38
123	Is amyloid-□an innocent bystander and marker in Alzheimer's disease? Is the liability of multivalent cation homeostasis and its influence on amyloid-□function the real mechanism?. *Journal of Alzheimer's Disease*, **2014**, 42, 69-85	4.3	11
122	The sex-specific associations of the aromatase gene with Alzheimer's disease and its interaction with IL10 in the Epistasis Project. *European Journal of Human Genetics*, **2014**, 22, 216-20	5.3	32

121	Renin Angiotensin aldosterone system inhibition in controlling dementia-related cognitive decline. *Journal of Alzheimer's Disease*, **2014**, 42 Suppl 4, S575-86	4.3	27
120	Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease. *Journal of Alzheimer's Disease*, **2014**, 40, 595-603	4.3	53
119	A degradation or cerebral perfusion? Divergent effects of multifunctional enzymes. *Frontiers in Aging Neuroscience*, **2014**, 6, 238	5.3	34
118	Environmental enrichment lessens cognitive decline in APP23 mice without affecting brain sirtuin expression. *Journal of Alzheimer's Disease*, **2014**, 42, 851-64	4.3	27
117	Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia. *Brain*, **2014**, 137, 1524-32	11.2	75
116	The branched-chain aminotransferase proteins: novel redox chaperones for protein disulfide isomerase--implications in Alzheimer's disease. *Antioxidants and Redox Signaling*, **2014**, 20, 2497-513	8.4	19
115	Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. *American Journal of Neurodegenerative Disease*, **2014**, 3, 19-32	2.5	89
114	Discovery by the Epistasis Project of an epistatic interaction between the GSTM3 gene and the HHEX/IDE/KIF11 locus in the risk of Alzheimer's disease. *Neurobiology of Aging*, **2013**, 34, 1309.e1-7	5.6	24
113	VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro. *American Journal of Pathology*, **2013**, 183, 918-29	5.8	78
112	Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. *Age*, **2013**, 35, 441-53		29
111	Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease. *Expert Opinion on Investigational Drugs*, **2013**, 22, 1229-42	5.9	41
110	Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier. *Chemical Reviews*, **2013**, 113, 1877-903	68.1	160
109	The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian case-control cohorts. *Alzheimer's and Dementia*, **2013**, 9, 392-9	1.2	36
108	The association between APOE ε4 and Alzheimer-type dementia among memory clinic patients is confined to those with a higher education. The DESCRIPA Study. *Journal of Alzheimer's Disease*, **2013**, 35, 241-6	4.3	6
107	Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study. *Dementia and Geriatric Cognitive Disorders*, **2013**, 36, 1-19	2.6	32
106	Using Alzgene-like approaches to investigate susceptibility genes for vascular cognitive impairment. *Journal of Alzheimer's Disease*, **2013**, 34, 145-54	4.3	26
105	Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. *Journal of Alzheimer's Disease*, **2013**, 33, 999-1008	4.3	25
104	Use of angiotensin-converting enzyme inhibitors for Alzheimer's disease: an update. *Neurodegenerative Disease Management*, **2013**, 3, 511-514	2.8	

103	Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-β levels and Braak stage. *PLoS ONE*, **2013**, 8, e59554	3.7	23
102	Influence of LRP-1 and apolipoprotein E on amyloid-β uptake and toxicity to cerebrovascular smooth muscle cells. *Journal of Alzheimer's Disease*, **2013**, 33, 95-110	4.3	23
101	BIN1 is decreased in sporadic but not familial Alzheimer's disease or in aging. *PLoS ONE*, **2013**, 8, e78806	3.7	49
100	An exploration of the potential mechanisms and translational potential of five medicinal plants for applications in Alzheimer's disease. *American Journal of Neurodegenerative Disease*, **2013**, 2, 70-88	2.5	7
99	Activators and inhibitors of the plasminogen system in Alzheimer's disease. *Journal of Cellular and Molecular Medicine*, **2012**, 16, 865-76	5.6	27
98	Drug repositioning for Alzheimer's disease. *Nature Reviews Drug Discovery*, **2012**, 11, 833-46	64.1	191
97	Clusterin mRNA and protein in Alzheimer's disease. *Journal of Alzheimer's Disease*, **2012**, 28, 337-44	4.3	19
96	Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project. *Neurobiology of Aging*, **2012**, 33, 202.e1-13	5.6	43
95	Assessment of activation of the plasma kallikrein-kinin system in frontal and temporal cortex in Alzheimer's disease and vascular dementia. *Neurobiology of Aging*, **2012**, 33, 1345-55	5.6	29
94	Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease. *RSC Advances*, **2012**, 2, 5008	3.7	44
93	LRP1 expression in cerebral cortex, choroid plexus and meningeal blood vessels: relationship to cerebral amyloid angiopathy and APOE status. *Neuroscience Letters*, **2012**, 525, 123-8	3.3	14
92	Distribution of the branched chain aminotransferase proteins in the human brain and their role in glutamate regulation. *Journal of Neurochemistry*, **2012**, 123, 997-1009	6	45
91	Interaction of insulin and PPAR-γ genes in Alzheimer's disease: the Epistasis Project. *Journal of Neural Transmission*, **2012**, 119, 473-9	4.3	19
90	Calcium channel blockers and Alzheimer's disease: potential relevance in treatment strategies of metabolic syndrome. *Journal of Alzheimer's Disease*, **2012**, 30 Suppl 2, S269-82	4.3	23
89	The role of variation at APP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. *Journal of Alzheimer's Disease*, **2012**, 28, 377-87	4.3	47
88	The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis?. *Journal of Alzheimer's Disease*, **2012**, 30 Suppl 2, S251-68	4.3	48
87	Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-β *Journal of Alzheimer's Disease*, **2012**, 29, 853-61	4.3	81
86	CNS SIRT3 expression is altered by reactive oxygen species and in Alzheimer's disease. *PLoS ONE*, **2012**, 7, e48225	3.7	87

85	Genetic variation in MME in relation to neprilysin protein and enzyme activity, A levels, and Alzheimer's disease risk. *International Journal of Molecular Epidemiology and Genetics*, **2012**, 3, 30-8	0.9	11
84	Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse. *American Journal of Translational Research (discontinued)*, **2012**, 4, 151-64	3	13
83	Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease. *American Journal of Neurodegenerative Disease*, **2012**, 1, 266-79	2.5	15
82	A multi-center study of ACE and the risk of late-onset Alzheimer's disease. *Journal of Alzheimer's Disease*, **2011**, 24, 587-97	4.3	29
81	A degrading enzymes: potential for treatment of Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*, **2011**, 70, 944-59	3.1	185
80	Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. *Journal of Alzheimer's Disease*, **2011**, 26, 699-708	4.3	168
79	Accumulation of insoluble amyloid- in down's syndrome is associated with increased BACE-1 and neprilysin activities. *Journal of Alzheimer's Disease*, **2011**, 23, 101-8	4.3	28
78	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nature Genetics*, **2011**, 43, 429-35	36.3	1421
77	Neprilysin protects against cerebral amyloid angiopathy and A induced degeneration of cerebrovascular smooth muscle cells. *Brain Pathology*, **2011**, 21, 594-605	6	33
76	Angiotensin-converting enzyme (ACE) genotypes and disability in hospitalized older patients. *Age*, **2011**, 33, 409-19		2
75	Antioxidant and anti-inflammatory effects of Scoparia dulcis L. *Journal of Medicinal Food*, **2011**, 14, 1576-82	2.2	14
74	Regional differences in effects of APOE 4 on cognitive impairment in non-demented subjects. *Dementia and Geriatric Cognitive Disorders*, **2011**, 32, 135-42	2.6	13
73	Angiotensin II-inhibiting drugs have no effect on intraneuronal A or oligomeric A levels in a triple transgenic mouse model of Alzheimer's disease. *American Journal of Translational Research (discontinued)*, **2011**, 3, 197-208	3	21
72	Tumour necrosis factor- (TNF-) and miRNA expression in frontal and temporal neocortex in Alzheimer's disease and the effect of TNF- on miRNA expression in vitro. *International Journal of Molecular Epidemiology and Genetics*, **2011**, 2, 156-62	0.9	15
71	The influence of tumour necrosis factor- (TNF-) on amyloid- (A)-degrading enzymes in vitro. *International Journal of Molecular Epidemiology and Genetics*, **2011**, 2, 409-15	0.9	3
70	Aluminium in the Diet, Cognitive Decline and Dementia **2011**, 2829-2850		
69	Alcohol Consumption in Predementia and Dementia Syndromes **2011**, 3011-3044		
68	Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid- *Journal of Alzheimer's Disease*, **2010**, 22, 1363-73	4.3	34

67	Endothelin-converting enzyme-1 in Alzheimer's disease and vascular dementia. *Neuropathology and Applied Neurobiology*, **2010**, 36, 487-97	5.2	27
66	Oligomeric Abeta in Alzheimer's disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. *Brain Pathology*, **2010**, 20, 468-80	6	44
65	Higher soluble amyloid beta concentration in frontal cortex of young adults than in normal elderly or Alzheimer's disease. *Brain Pathology*, **2010**, 20, 787-93	6	38
64	Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. *Brain Pathology*, **2010**, 20, 794-802	6	76
63	Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. *PLoS ONE*, **2010**, 5, e13950	3.7	276
62	Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's disease. *PLoS ONE*, **2010**, 5, e8764	3.7	40
61	Angiotensin receptor blockers associated with decreased incidence and progression of dementia in older men with cardiovascular disease. *Evidence-Based Mental Health*, **2010**, 13, 75	11.1	
60	Distribution and expression of picalm in Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*, **2010**, 69, 1071-7	3.1	76
59	Aluminum in the Diet and Alzheimer's Disease: From Current Epidemiology to Possible Disease-Modifying Treatment. *Journal of Alzheimer's Disease*, **2010**, 20, 17-30	4.3	67
58	Plasminogen and plasmin in Alzheimer's disease. *Brain Research*, **2010**, 1355, 7-15	3.7	32
57	Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia. *Brain Research*, **2010**, 1363, 1-10	3.7	33
56	The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project. *BMC Medical Genetics*, **2010**, 11, 162	2.1	43
55	ACE variants and association with brain Aβ levels in Alzheimer's disease. *American Journal of Translational Research (discontinued)*, **2010**, 3, 73-80	3	31
54	LRP-1 variation is not associated with risk of Alzheimer's disease. *International Journal of Molecular Epidemiology and Genetics*, **2010**, 1, 104-13	0.9	8
53	Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy. *Frontiers in Bioscience - Landmark*, **2009**, 14, 4778-92	2.8	50
52	Ethical aspects of research into Alzheimer disease. A European Delphi Study focused on genetic and non-genetic research. *Journal of Medical Ethics*, **2009**, 35, 140-4	2.5	17
51	Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. *Journal of Neuropathology and Experimental Neurology*, **2009**, 68, 902-14	3.1	78
50	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nature Genetics*, **2009**, 41, 1088-93	36.3	2018

49	Angiotensins in Alzheimer's disease - friend or foe?. *Trends in Neurosciences*, **2009**, 32, 619-28	13.3	135
48	TNFR-associated factor-2 (TRAF-2) in Alzheimer's disease. *Neurobiology of Aging*, **2009**, 30, 1052-60	5.6	16
47	Alpha-2-macroglobulin gene, oxidized low-density lipoprotein receptor-1 locus, and sporadic Alzheimer's disease. *Neurobiology of Aging*, **2009**, 30, 1518-20	5.6	8
46	Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. *Journal of Neuroinflammation*, **2009**, 6, 22	10.1	41
45	Angiotensins and Alzheimer's disease: a bench to bedside overview. *Alzheimer's Research and Therapy*, **2009**, 1, 3	9	28
44	Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta. *American Journal of Pathology*, **2009**, 175, 262-70	5.8	87
43	Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. *American Journal of Translational Research (discontinued)*, **2009**, 1, 163-77	3	88
42	Abeta-degrading enzymes in Alzheimer's disease. *Brain Pathology*, **2008**, 18, 240-52	6	279
41	Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. *Neuropathology and Applied Neurobiology*, **2008**, 34, 181-93	5.2	106
40	MMP-2, -3 and -9 levels and activity are not related to Abeta load in the frontal cortex in Alzheimer's disease. *Neuropathology and Applied Neurobiology*, **2008**, 34, 205-15	5.2	27
39	Evidence that the gene encoding insulin degrading enzyme influences human lifespan. *Human Molecular Genetics*, **2008**, 17, 2370-8	5.6	8
38	Clearance of Abeta from the brain in Alzheimer's disease. Foreword. *Brain Pathology*, **2008**, 18, 239	6	1
37	Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. *Journal of Neuroscience Methods*, **2008** , 167, 229-36	3	39
36	Immunocapture-based fluorometric assay for the measurement of insulin-degrading enzyme activity in brain tissue homogenates. *Journal of Neuroscience Methods*, **2008**, 169, 177-81	3	26
35	Caveolin-1 and -2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease. *Neuropathology and Applied Neurobiology*, **2007**, 33, 317-27	5.2	23
34	Protein and gene expression of tumour necrosis factor receptors I and II and their promoter gene polymorphisms in Alzheimer's disease. *Experimental Gerontology*, **2007**, 42, 538-44	4.5	13
33	Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?. *Lancet Neurology, The*, **2007**, 6, 373-8	24.1	145
32	Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE. *Neurobiology of Aging*, **2007**, 28, 1374-80	5.6	32

31	Differences in allele frequencies of ACE I/D polymorphism between Northern and Southern Europe at different ages. *Atherosclerosis*, **2007**, 193, 455-7	3.1	6
30	Sex differences in the association of apolipoprotein E and angiotensin-converting enzyme gene polymorphisms with healthy aging and longevity: a population-based study from Southern Italy. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2006**, 61, 918-23	6.4	62
29	Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. *Journal of Neuropathology and Experimental Neurology*, **2006**, 65, 1012-21	3.1	112
28	Commentary (The Renin Angiotensin System in Alzheimers Disease - Do Updates Highlight a Clinical and Biological Dichotomy?). *Current Alzheimer Research*, **2006**, 3, 171-173	3	3
27	Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer's disease. *Neuroscience Letters*, **2006**, 408, 141-5	3.3	14
26	Current knowledge of chromosome 12 susceptibility genes for late-onset Alzheimer's disease. *Neurobiology of Aging*, **2006**, 27, 1537-53	5.6	20
25	The cardiovascular and respiratory health of people with schizophrenia. *Acta Psychiatrica Scandinavica*, **2006**, 113, 298-305	6.5	99
24	Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain. *Neurobiology of Aging*, **2005**, 26, 795-802	5.6	42
23	Molecular determinants of human longevity. *Advances in Clinical Chemistry*, **2005**, 39, 185-210	5.8	1
22	Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. *American Journal of Epidemiology*, **2005**, 162, 305-17	3.8	170
21	A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity. *Human Molecular Genetics*, **2004**, 13, 2647-57	5.6	47
20	Vascular genetic factors and human longevity. *Mechanisms of Ageing and Development*, **2004**, 125, 169-78	3.6	30
19	Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease. *Human Genetics*, **2004**, 114, 478-83	6.3	33
18	Vascular risk and genetics of sporadic late-onset Alzheimer's disease. *Journal of Neural Transmission* , **2004**, 111, 69-89	4.3	58
17	Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. *Human Mutation*, **2004**, 23, 358-67	4.7	114
16	APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease. *NeuroReport*, **2004**, 15, 95-8	1.7	34
15	Angiotensin I converting enzyme (ACE) gene polymorphism in centenarians: different allele frequencies between the North and South of Europe. *Experimental Gerontology*, **2003**, 38, 1015-20	4.5	52
14	Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease. *Neuroscience Letters*, **2003**, 350, 61-5	3.3	55

13	Haplotypes extending across ACE are associated with Alzheimer's disease. *Human Molecular Genetics*, **2003**, 12, 859-67	5.6	93
12	The renin-angiotensin-aldosterone system and Alzheimer s disease?. *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, **2003**, 4, 80-93	3	34
11	APOE epsilon 4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome. *British Journal of Psychiatry*, **2000**, 176, 468-72	5.4	54
10	Familial influence on variation in age of onset and behavioural phenotype in Alzheimer's disease. *British Journal of Psychiatry*, **2000**, 176, 156-9	5.4	50
9	A full genome scan for late onset Alzheimer's disease. *Human Molecular Genetics*, **1999**, 8, 237-45	5.6	279
8	Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. *Nature Genetics*, **1999**, 21, 71-2	36.3	236
7	Alpha-2 macroglobulin gene and Alzheimer disease. *Nature Genetics*, **1999**, 22, 17-9; author reply 21-2	36.3	88
6	No association between the alpha-2 macroglobulin I1000V polymorphism and Alzheimer's disease. *Neuroscience Letters*, **1999**, 262, 137-9	3.3	45
5	Genetic variability at the amyloid-beta precursor protein locus may contribute to the risk of late-onset Alzheimer's disease. *Neuroscience Letters*, **1999**, 269, 67-70	3.3	39
4	Presenilin-1 polymorphism and Alzheimer's disease. *Lancet, The*, **1996**, 348, 414	40	1
3	Presenilin-1 polymorphism and Alzheimer's disease. *Lancet, The*, **1996**, 347, 1185-1187	40	54
2	New insights on the genetic etiology of Alzheimer and related dementia		25
1	Repurposing antihypertensive drugs for the prevention of Alzheimer disease: a Mendelian Randomization study		1